查看购物车
  • Traditional Chinese
  • English
  • Japanese
医疗保健生成式人工智慧的全球市场：按应用程式和最终用户划分 - 机会分析和行业预测，2023-2032 年
市场调查报告书
商品编码
1414850

医疗保健生成式人工智慧的全球市场：按应用程式和最终用户划分 - 机会分析和行业预测，2023-2032 年

Generative Ai In Healthcare Market By Application (Treatment, Diagnosis, Drug Discovery, Research), By End User (Hospitals and clinics, Healthcare Organizations, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3个工作天内

价格

预计2022年全球医疗保健生成人工智慧市场规模将达16亿美元，2023年至2032年复合年增长率为34.9%，2032年将达304亿美元。

医疗保健市场中的生成人工智慧-IMG1

生成式人工智慧正成为医疗保健领域的一股变革力量，而医学影像处理中的应用则成为医疗保健市场中生成式人工智慧的成长动力。生成式人工智慧在医学影像处理中最有吸引力的应用之一是医学影像增强和重建。生成对抗网路 (GAN) 和其他生成模型提高了影像解析度和质量，帮助临床医生做出更准确的诊断。例如，根据国家医学图书馆 2023 年的一份报告，产生人工智慧 (AI) 显示出增强医疗图像任务的巨大潜力，例如：

1）资料增强、影像合成、影像之间的转换、放射诊断报告创建。

此外，产生的人工智慧在医疗保健临床资料管理中的效率预计将显着促进市场成长。事实证明，由先进的自然语言处理和机器学习技术支援的生成式人工智慧在改变医疗机构处理和利用大量临床资料的方式方面具有不可估量的价值。产生人工智慧最吸引人的方面之一是它能够自动化和简化复杂的资料管理任务。生成式人工智慧可以从各种来源提取、组织和分类临床资料，包括电子健康记录、医学影像和病患笔记，速度和准确性令人印象深刻。这不仅减轻了医疗保健专业人员的负担，使他们能够更多地关注患者照护，还显着提高了基于证据的决策、研究和患者定制治疗计划所必需的资料的准确性和完整性。例如，2021 年，领先的医疗保健提供者之一 HCA Healthcare, Inc. 与 Google Cloud 宣布建立多年策略合作伙伴关係。 HCA Healthcare 与 Google Cloud 合作，利用生成式 AI 帮助医生和护士减轻业务负担。

此外，生成式人工智慧的效率不仅限于资料组织。透过整合不同来源的信息，您可以产生全面的临床报告、摘要和预测模型。这项功能不仅节省时间，还有助于早期疾病检测、治疗优化和预后评估。此外，不断学习和适应新资料的能力使医疗保健组织能够及时了解最新的医学研究和最佳实践，最终改善患者的治疗结果。然而，资料隐私问题可能会限制市场成长。

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 医疗影像领域越来越多地采用生成式人工智慧
      • 生成式人工智慧在工作流程和管理业务中的效率
      • 生成式人工智慧在个人化医疗的应用
    • 抑制因素
      • 资料隐私/安全风险
    • 机会
      • 生成式人工智慧在药物研发发现与开发的应用

第四章医疗保健生成人工智慧市场：按应用分类

  • 概述
  • 治疗
  • 诊断
  • 药物研发
  • 研究

第五章医疗保健生成式人工智慧市场：依最终用户分类

  • 概述
  • 医院/诊所
  • 医疗保健组织
  • 其他的

第六章医疗保健生成人工智慧市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 澳洲
    • 印度
    • 韩国
    • 其他亚太地区
  • 拉丁美洲、中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他拉丁美洲、中东/非洲

第七章 竞争形势

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第八章 公司简介

  • Syntegra
  • IBM Watson Health Corporation
  • Google LLC
  • Amazon
  • Oracle
  • Microsoft
  • NVIDIA Corporation
  • InSilico Medicine
  • Abridge AI Inc.
  • Open AI Inc.
Product Code: A156675

According to a new report published by Allied Market Research, titled, "Generative AI in Healthcare Market," The generative AI in the healthcare market was valued at $1.6 billion in 2022, and is estimated to reach $30.4 billion by 2032, growing at a CAGR of 34.9% from 2023 to 2032.

Generative Ai In Healthcare Market - IMG1

Generative AI has emerged as a transformative force in the field of healthcare, with its applications in medical imaging standing out as a major driver for the growth of generative AI in the healthcare market. One of the most compelling applications of generative AI in medical imaging is in the enhancement and reconstruction of medical images. Generative Adversarial Networks (GANs) and other generative models can improve the resolution and quality of images, aiding clinicians in making more accurate diagnoses. For instance, according to a 2023 report by the National Library of Medicine, generative artificial intelligence (AI) has shown great potential in enhancing medical imaging tasks such as data augmentation, image synthesis, image-to-image translation, and radiology report generation.

Furthermore, the efficiency of generative AI in healthcare in clinical data management is expected to contribute significantly to the growth of the market. Generative AI, powered by advanced natural language processing and machine learning techniques, has proven itself invaluable in transforming the way healthcare institutions handle and utilize vast volumes of clinical data. One of the most compelling aspects of generative AI is its ability to automate and streamline complex data management tasks. Generative AI can extract, organize, and categorize clinical data from a variety of sources, including electronic health records, medical imaging, and patient notes, with remarkable speed and precision. This not only reduces the burden on healthcare professionals, allowing them to focus more on patient care, but also significantly enhances the accuracy and completeness of data, which is crucial for evidence-based decision-making, research, and personalized patient treatment plans. For instance, in 2021, HCA Healthcare, Inc., one of the leading healthcare providers, and Google Cloud announced a multi-year strategic partnership. HCA Healthcare collaborated with Google Cloud on the use of generative AI to support doctors and nurses to reduce the burden of administrative tasks.

Moreover, generative AI's efficiency extends beyond data organization. It can generate comprehensive clinical reports, summaries, and predictive models by synthesizing information from disparate sources. This capability not only saves time but also aids in early disease detection, treatment optimization, and prognosis assessment. Additionally, its ability to continually learn and adapt from new data ensures that healthcare organizations stay up-to-date with the latest medical research and best practices, ultimately leading to improved patient outcomes. However, concerns related to data privacy might restrain the growth of the market.

The generative AI in healthcare market is segmented on the basis of application, end user, and region. By applications, the market is categorized into treatment, diagnosis, drug discovery, and research. As per end users, the market is categorized into hospitals & clinics, healthcare organizations, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global generative AI in the healthcare market are IBM Watson Health Corporation, Google LLC, Syntegra, Amazon, Open AI, NVIDIA Corporation, Oracle, Insilico Medicine, Abridge AI Inc, and Microsoft.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the generative AI in healthcare market analysis from 2022 to 2032 to identify the prevailing generative ai in healthcare market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • An in-depth analysis of the generative ai in healthcare market segmentation assists in determining the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes an analysis of the regional as well as global generative AI in healthcare market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Application

  • Treatment
  • Diagnosis
  • Drug Discovery
  • Research

By End User

  • Hospitals and clinics
  • Healthcare Organizations
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • IBM Watson Health Corporation
    • Amazon
    • Microsoft
    • Open AI Inc.
    • Google LLC
    • NVIDIA Corporation
    • Abridge AI Inc.
    • Syntegra
    • InSilico Medicine
    • Oracle

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Surge in adoption of generative AI in healthcare in medical imaging.
      • 3.4.1.2. Efficiency of generative AI in workflow and administrative tasks.
      • 3.4.1.3. Use of generative AI in personalized medicine.
    • 3.4.2. Restraints
      • 3.4.2.1. Data privacy and security risk.
    • 3.4.3. Opportunities
      • 3.4.3.1. Use of generative AI in drug discovery development

CHAPTER 4: GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Treatment
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Diagnosis
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Drug Discovery
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Research
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: GENERATIVE AI IN HEALTHCARE MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospitals and clinics
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Healthcare Organizations
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: GENERATIVE AI IN HEALTHCARE MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Application
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Application
      • 6.2.4.1.2. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Application
      • 6.2.4.2.2. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Application
      • 6.2.4.3.2. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Application
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Application
      • 6.3.4.1.2. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Application
      • 6.3.4.2.2. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Application
      • 6.3.4.3.2. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Market size and forecast, by Application
      • 6.3.4.4.2. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Market size and forecast, by Application
      • 6.3.4.5.2. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Application
      • 6.3.4.6.2. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Application
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Application
      • 6.4.4.1.2. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Application
      • 6.4.4.2.2. Market size and forecast, by End User
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Market size and forecast, by Application
      • 6.4.4.3.2. Market size and forecast, by End User
      • 6.4.4.4. India
      • 6.4.4.4.1. Market size and forecast, by Application
      • 6.4.4.4.2. Market size and forecast, by End User
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Application
      • 6.4.4.5.2. Market size and forecast, by End User
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Application
      • 6.4.4.6.2. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Application
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Application
      • 6.5.4.1.2. Market size and forecast, by End User
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Application
      • 6.5.4.2.2. Market size and forecast, by End User
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Application
      • 6.5.4.3.2. Market size and forecast, by End User
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Application
      • 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Syntegra
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Key strategic moves and developments
  • 8.2. IBM Watson Health Corporation
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. Google LLC
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Amazon
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
  • 8.5. Oracle
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
  • 8.6. Microsoft
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. NVIDIA Corporation
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. InSilico Medicine
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
  • 8.9. Abridge AI Inc.
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
  • 8.10. Open AI Inc.
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 02. GENERATIVE AI IN HEALTHCARE MARKET FOR TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GENERATIVE AI IN HEALTHCARE MARKET FOR DIAGNOSIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GENERATIVE AI IN HEALTHCARE MARKET FOR DRUG DISCOVERY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GENERATIVE AI IN HEALTHCARE MARKET FOR RESEARCH, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 07. GENERATIVE AI IN HEALTHCARE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GENERATIVE AI IN HEALTHCARE MARKET FOR HEALTHCARE ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GENERATIVE AI IN HEALTHCARE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GENERATIVE AI IN HEALTHCARE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA GENERATIVE AI IN HEALTHCARE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. U.S. GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. U.S. GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. CANADA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. CANADA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. MEXICO GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. EUROPE GENERATIVE AI IN HEALTHCARE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. FRANCE GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. FRANCE GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. UK GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. UK GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. ITALY GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. ITALY GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. SPAIN GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. SPAIN GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC GENERATIVE AI IN HEALTHCARE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. JAPAN GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. JAPAN GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. CHINA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. CHINA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. AUSTRALIA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. AUSTRALIA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. INDIA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. INDIA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. SOUTH KOREA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. LAMEA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. LAMEA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. LAMEA GENERATIVE AI IN HEALTHCARE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. BRAZIL GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. BRAZIL GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. SAUDI ARABIA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. SAUDI ARABIA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. SOUTH AFRICA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. SOUTH AFRICA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. REST OF LAMEA GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. REST OF LAMEA GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. SYNTEGRA: KEY EXECUTIVES
  • TABLE 62. SYNTEGRA: COMPANY SNAPSHOT
  • TABLE 63. SYNTEGRA: PRODUCT SEGMENTS
  • TABLE 64. SYNTEGRA: PRODUCT PORTFOLIO
  • TABLE 65. SYNTEGRA: KEY STRATERGIES
  • TABLE 66. IBM WATSON HEALTH CORPORATION: KEY EXECUTIVES
  • TABLE 67. IBM WATSON HEALTH CORPORATION: COMPANY SNAPSHOT
  • TABLE 68. IBM WATSON HEALTH CORPORATION: PRODUCT SEGMENTS
  • TABLE 69. IBM WATSON HEALTH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 70. GOOGLE LLC: KEY EXECUTIVES
  • TABLE 71. GOOGLE LLC: COMPANY SNAPSHOT
  • TABLE 72. GOOGLE LLC: SERVICE SEGMENTS
  • TABLE 73. GOOGLE LLC: PRODUCT PORTFOLIO
  • TABLE 74. GOOGLE LLC: KEY STRATERGIES
  • TABLE 75. AMAZON: KEY EXECUTIVES
  • TABLE 76. AMAZON: COMPANY SNAPSHOT
  • TABLE 77. AMAZON: PRODUCT SEGMENTS
  • TABLE 78. AMAZON: PRODUCT PORTFOLIO
  • TABLE 79. ORACLE: KEY EXECUTIVES
  • TABLE 80. ORACLE: COMPANY SNAPSHOT
  • TABLE 81. ORACLE: SERVICE SEGMENTS
  • TABLE 82. ORACLE: PRODUCT PORTFOLIO
  • TABLE 83. MICROSOFT: KEY EXECUTIVES
  • TABLE 84. MICROSOFT: COMPANY SNAPSHOT
  • TABLE 85. MICROSOFT: SERVICE SEGMENTS
  • TABLE 86. MICROSOFT: PRODUCT PORTFOLIO
  • TABLE 87. MICROSOFT: KEY STRATERGIES
  • TABLE 88. NVIDIA CORPORATION: KEY EXECUTIVES
  • TABLE 89. NVIDIA CORPORATION: COMPANY SNAPSHOT
  • TABLE 90. NVIDIA CORPORATION: PRODUCT SEGMENTS
  • TABLE 91. NVIDIA CORPORATION: PRODUCT PORTFOLIO
  • TABLE 92. NVIDIA CORPORATION: KEY STRATERGIES
  • TABLE 93. INSILICO MEDICINE: KEY EXECUTIVES
  • TABLE 94. INSILICO MEDICINE: COMPANY SNAPSHOT
  • TABLE 95. INSILICO MEDICINE: PRODUCT SEGMENTS
  • TABLE 96. INSILICO MEDICINE: PRODUCT PORTFOLIO
  • TABLE 97. ABRIDGE AI INC.: KEY EXECUTIVES
  • TABLE 98. ABRIDGE AI INC.: COMPANY SNAPSHOT
  • TABLE 99. ABRIDGE AI INC.: PRODUCT SEGMENTS
  • TABLE 100. ABRIDGE AI INC.: PRODUCT PORTFOLIO
  • TABLE 101. OPEN AI INC.: KEY EXECUTIVES
  • TABLE 102. OPEN AI INC.: COMPANY SNAPSHOT
  • TABLE 103. OPEN AI INC.: PRODUCT SEGMENTS
  • TABLE 104. OPEN AI INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF GENERATIVE AI IN HEALTHCARE MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN GENERATIVE AI IN HEALTHCARE MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN GENERATIVE AI IN HEALTHCARE MARKET (2023-2032)
  • FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. LOW THREAT OF NEW ENTRANTS
  • FIGURE 07. LOW THREAT OF SUBSTITUTES
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. LOW BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL GENERATIVE AI IN HEALTHCARE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. GENERATIVE AI IN HEALTHCARE MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF GENERATIVE AI IN HEALTHCARE MARKET FOR TREATMENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF GENERATIVE AI IN HEALTHCARE MARKET FOR DIAGNOSIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF GENERATIVE AI IN HEALTHCARE MARKET FOR DRUG DISCOVERY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF GENERATIVE AI IN HEALTHCARE MARKET FOR RESEARCH, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. GENERATIVE AI IN HEALTHCARE MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GENERATIVE AI IN HEALTHCARE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF GENERATIVE AI IN HEALTHCARE MARKET FOR HEALTHCARE ORGANIZATIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF GENERATIVE AI IN HEALTHCARE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. GENERATIVE AI IN HEALTHCARE MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 21. U.S. GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. CANADA GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. MEXICO GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. GERMANY GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. FRANCE GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. UK GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. ITALY GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. SPAIN GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. REST OF EUROPE GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. JAPAN GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CHINA GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. AUSTRALIA GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. INDIA GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SOUTH KOREA GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF ASIA-PACIFIC GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. BRAZIL GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SAUDI ARABIA GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SOUTH AFRICA GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF LAMEA GENERATIVE AI IN HEALTHCARE MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 41. COMPETITIVE DASHBOARD
  • FIGURE 42. COMPETITIVE HEATMAP: GENERATIVE AI IN HEALTHCARE MARKET
  • FIGURE 43. TOP PLAYER POSITIONING, 2022
  • FIGURE 44. IBM WATSON HEALTH CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 45. IBM WATSON HEALTH CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 46. IBM WATSON HEALTH CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 47. GOOGLE LLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. GOOGLE LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. GOOGLE LLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 50. AMAZON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. AMAZON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. AMAZON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. ORACLE CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. ORACLE CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. ORACLE CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. MICROSOFT: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. MICROSOFT: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. MICROSOFT: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. NVIDIA CORPORATION: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 60. NVIDIA CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. NVIDIA CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. NVIDIA CORPORATION: REVENUE SHARE BY REGION, 2021 (%)